period seems to be similar for CAS and CEA, 3, 4 it has been suggested that CAS may be an acceptable option in selected patients who have a low procedural risk of stroke or death, as indicated in European and American guidelines. 5, 6 However, there is no indication as to how patients with a low procedural risk can be identified. The combined analysis of the large European trials and North American trials of CEA versus CAS has shown that CAS was potentially as safe as CEA in younger patients, 2, 7 but there remains uncertainty whether age should be used alone as a selection criteria to identify potential candidates for CAS. Other clinical factors are likely to influence the relative procedural risks of the 2 techniques, [8] [9] [10] [11] [12] some of which were not addressed in analysis of the randomized trials, and other important groups, such as patients with restenosis, were either excluded from the trials or not reported separately. 13 Moreover, the trials lack the statistical power to detect clinically important interactions between patient characteristics and treatment effect. 7 In contrast, numerous case series of patients undergoing CEA or CAS are available, and collectively provide data on the risk factors for procedural stroke and death for one or other procedure in several hundred thousand patients. [8] [9] [10] [11] [12] We have shown previously that meta-analysis of risk associations from such studies provides reliable and highly consistent data on the clinical characteristics associated with procedural risk of CEA and CAS independently. [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] To guide clinical decision making, we now aimed to use this approach to identify those predictors of procedural risk that differ significantly between CEA and CAS and might therefore be useful in determining which procedure is most appropriate in individual patients. We aimed to thereby derive a simple clinical risk rule to target CAS versus CEA and to validate the rule and determine its likely clinical use by using individual patient data from the randomized trials that directly compared CEA and CAS included in The Carotid Stenting Trialists' Collaboration (CSTC) Database.
7

Methods
Systematic Review of Observational Data
We updated our previous systematic reviews using the same selection criteria and search strategy as previously published, [8] [9] [10] [11] [12] 14 and following the Preferred Reporting Items for Systematic Reviews and MetaAnalyses (PRISMA) recommendations for reporting.
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Selection Criteria
Eligible studies were those which enrolled patients with symptomatic or asymptomatic stenosis located in the region of the carotid bifurcation, treated by CAS or CEA, and in which the numbers of stroke or death could be extracted for any subgroup among a predefined list of 9 risk factors: age (≥75-80 versus <75-80 years, ie, corresponding to the most common cutoffs used to separate elderly from nonelderly patients), contralateral carotid occlusion (severe stenosis was not considered), coronary artery disease, diabetes mellitus, sex (men versus women), hypertension, peripheral artery disease, type of stenosis (restenosis after CEA versus primary atherosclerotic disease), and side of stenosis (right versus left). These factors were identified as potentially relevant from previous systematic reviews or individual studies. [8] [9] [10] [11] [12] Studies were considered irrespective of setting and language. Observational studies were defined as cohorts or case series, including administrative databases, of patients undergoing CAS or CEA. We excluded studies that enrolled only specific populations (eg, postradiation stenosis, restenosis after CEA, and patients treated in an emergency context) and case reports.
Search Strategy
The search strategy was based primarily on an electronic search of 3 databases (Medical Literature Analysis and Retrieval System Online, Excerpta Medica, and the Cochrane Central Register of Controlled Trials databases) until July 1, 2011 (Table I in the online-only Data Supplement). We hand-searched the references of all included articles and any relevant reviews. We also searched books of abstracts from recent conferences that were available online (Table II in 
Study Selection and Data Collection
Assessment of eligibility of studies was performed by 2 independent reviewers for CAS and CEA separately, from the titles and abstracts as previously reported. [8] [9] [10] [11] [12] Final selection was made after reviewing full-text articles. Reviewers extracted information from the reports using a standardized data chart. For each report, a second reviewer ascertained the accuracy of data extracted by the first reviewer. Any disagreement was resolved by discussion.
The [ICSS] ), which formed the CSTC, 7 were used for the validation analyses, and the data from these trials were therefore not included in the systematic review of risk associations.
Analysis
The primary outcome was the procedural risk of stroke or death (most commonly defined as the risk during the 30 days after the procedure). Secondary outcomes were stroke and any death separately. Nonfatal myocardial infarction was not included. For each of the 9 potential risk factors and separately for studies of CAS and of CEA, we calculated the relative risks (RR) of a procedural event in patients versus those without the risk factor. Because of differences between studies in which risk factor data were reported, the numbers of studies (and patients) included in each meta-analysis differed. In each meta-analysis, studies with no events occurring in all groups (ie, patients with and without the risk factor) did not contribute to the calculation of the pooled RR. However, when zero cell count was observed in 1 group only, we used a continuity correction, by adding a factor proportional to the reciprocal of the size of the contrasting study group to all cells. 16 Homogeneity of RRs across studies in each meta-analysis was assessed using the I 2 statistic. I 2 >30% represents moderate heterogeneity, I 2 >50% substantial heterogeneity, and I 2 >70% considerable heterogeneity. We report pooled RRs computed through DerSimonian-Laird random effects meta-analyses, although analyses using fixed-effect meta-analysis models according to the Mantel-Haenszel method showed consistent results. For each risk factor, we assessed whether the effect on the procedural risk of event differed between CAS and CEA by performing an interaction test using random effects meta-regressions. As is recommended for such analyses, we considered a probability value of ≤0.10 as evidence of statistically significant interaction.
17
Derivation of the Rule
From the set of risk factors with differing effects between CAS and CEA (ie, with statistically significant interactions), we took the magnitude and direction of interactions into account to determine the rule. If a large qualitative interaction was found (ie, when RRs were clearly in opposite directions or when the difference from unity was ≥0.50 for the factor with the greater effect and ≤0.10 for the factor with the effect close to the unity), such a risk factor was considered sufficient by itself to identify low-risk patients. Otherwise, factors associated with a high risk after CAS scored +1 and those with a low risk scored −1. Patients with a total score <0 were categorized into low risk. In a secondary analysis, an alternative rule was also derived, in which all 
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factors were considered equivalent (high risk of CAS scores +1 and low risk for CAS scores −1), and patients were categorized according to the total score.
Validation of the Rule
After having derived the rule, P.M. Rothwell, E. Touzé, and L. Trinquart made a formal request to the CSTC to obtain a data set from EVA-3S, SPACE, and ICSS randomized trials to validate the rule. 7 At no time, did these researchers have access to the data set before they derived the rule. A per-protocol individual data set including the 30-day outcomes (stroke or death, stroke, death) occurrence and the risk factors selected for the clinical rule only were obtained. Definitions of outcomes and risk factors were already standardized across the 3 trials.
7 Patients were categorized into low or high risk according to the rule. We used a 2-stage meta-analytic approach. 18 First, in each low-risk and high-risk category and for CAS and CEA separately, we calculated combined absolute risks of procedural stroke or death. We used a DerSimonian-Laird random effects model to combine absolute risks across trials through the Freeman-Tukey variance stabilizing transformation. 19 Second, in each low-risk and high-risk category, we computed combined RR of stroke or death in patients treated with CAS compared with patients treated with CEA. We tested for interaction of treatment effect between low-and high-risk patients using meta-regression. Given the a priori prediction that the RR of stroke or death occurring in patients treated with CAS compared with patients treated with CEA would be higher in CAS-higher-risk than in CASlower-risk patients, we calculated a 1-sided probability value by using a Monte Carlo permutation test.
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Results
A total of 170 studies (227 articles, >70 000 patients) provided data for ≥1 of 9 potential risk factors: 115 studies (149 articles) relating to CEA and 68 studies (83 articles) relating to CAS, some being related to both CEA and CAS. The characteristics of these studies and the list of references are shown in Table I in the online-only Data Supplement.
The results of the meta-analyses of the RRs of stroke or death in relation to the 9 potential risk factors in CAS and CEA studies are shown in Figure 1 . There was no or little heterogeneity between studies in RRs for age, contralateral occlusion, diabetes mellitus, sex, hypertension, and restenosis among either CAS or CEA studies. The effects of age, sex, contralateral occlusion, and restenosis on the procedural risk of stroke or death differed statistically significantly between CAS and CEA (interaction test probability value of <0.10). There was more heterogeneity in RR between CEA studies concerning coronary artery disease, stenosis side, and peripheral artery disease, but the effects of these variables on the procedural risk of stroke or death did not differ statistically significantly between CAS and CEA.
Age was associated with higher risks of procedural stroke or death for both CAS and CEA but the increase in risk was greater after CAS. Contralateral occlusion and female sex were associated with a higher risk of procedural stroke or death after CEA but had no significant influence on the risk after CAS. Compared with patients with primary atherosclerotic disease, those with restenosis after CEA had a higher risk of procedural stroke or death when treated by CEA but a lower risk when treated by CAS. Analyses based on stroke only yielded qualitatively similar results ( Figure I in the onlineonly Data Supplement).
Therefore, the resulting rule was based on the presence or absence of the 4 following factors: sex, contralateral occlusion, age and restenosis (SCAR rule). Given the large qualitative Figure 1 . Meta-analyses of the relative risk of stroke or death after carotid angioplasty and stenting (CAS) and carotid endarterectomy (CEA) according to the 9 potential risk factors. N indicates number of studies; n1, number of events in patients with clinical factor; N1, number of patients with clinical factor; n0, number of events in patients without clinical factor; N0, number of patients without clinical factor; P het , Cochran homogeneity test probability value; P int , P interaction; P sig , P significance; and RR, relative risk.
by guest on October 15, 2017 http://stroke.ahajournals.org/ Downloaded from effect of contralateral occlusion and restenosis, we first considered that these risk factors were by themselves sufficient to identify patients in whom CAS would be relatively lower risk (SCAR negative) and comparable with CEA. Otherwise, given the smaller qualitative interaction for sex and the small quantitative interaction for age, only women <75 years would also be expected to be relatively at low risk for CAS (also SCAR negative), all other patients being categorized as higher risk (SCAR positive) for CAS and therefore as candidates for CEA preferentially. In a secondary analysis, we considered all factors equivalent, that is, that all patients with ≥2 factors (age <75 years, women, contralateral occlusion, or restenosis) would be SCAR negative and all others SCAR positive. The only difference between the 2 options being that men >75 years with contralateral carotid occlusion or restenosis are SCAR positive in the second option (Table II in the onlineonly Data Supplement).
Among the 4 components of the SCAR rule, effects of sex, contralateral occlusion, and age could be validated with the individual data from the CSTC, but patients with restenosis were excluded from the trials. Data on contralateral carotid occlusion were missing in 275 patients (262 from SPACE and 13 from ICSS). Exclusion of these patients left 3049 patients for the analyses. Using our primary definition of the SCAR rule, 694 (22·8%) patients were classified as SCAR negative: 135 patients had contralateral carotid occlusion, and the other 559 patients were women <75 years. Among these SCARnegative patients, the absolute risks of any stroke or death were similar between CAS and CEA (absolute risks 5.6%, 95% confidence interval [3.0-9 .0] versus 5.6% [3.4-8.4] ). However, among SCAR-positive patients, the absolute risk of CAS was more than twice that of CEA (8.4%, 6.9-10.1 versus 3.5%, 2.6-4.6; Figure II in the online-only Data Supplement). Figure 2 shows the RRs of any procedural stroke or death occurring in patients treated by CAS compared with patients treated by CEA. Among SCAR-negative patients, the pooled RR was 0.93 (95% confidence interval [0.49-1.76], I 2 =0%; P (sig)=0.83) whereas, among SCAR-positive patients, it was 2.44 (1.71-3.48, I 2 =0%; P (sig)<0.0001). The interaction was statistically significant (P=0.05). Analyses based on the procedural risk of stroke (RR=0.93; 0.48-1.80 in SCARnegative patients versus 2.45; 1.70-3.64 in SCAR-positive patients; P for interaction=0.05; Figure In the absence of contralateral occlusion and restenosis, only women <75 years are identified as low risk for CAS by the SCAR rule, consistent with the finding that men aged <75 years without contralateral carotid occlusion remained at higher risk of procedural stroke or death when treated by CAS versus CEA (RR=1.94; 95% confidence interval [1.22-3.07] ).
Finally, considering that CSTC and CREST have both shown that CAS is not inferior to CEA in patients <70 years (rather than the 75-year cut point derived from our systematic review), we performed a sensitivity analysis including only patients who were SCAR positive and aged <70 years from the CSTC data set (data obtained secondarily from the CSTC). In this subset of patients, the trend toward a higher procedural risk of stroke or death with CAS compared with CEA remained (RR=1.77; 95% confidence interval [0.98-3.21]).
Discussion
We have derived and partially validated a simple rule to categorize patients with severe symptomatic carotid stenosis according to their RR of periprocedural stroke or death with CAS versus CEA and to thereby identify a subset of patients in whom CAS may be noninferior to CEA. We used the strongest evidence available from large systematic reviews to identify the relevant risk factors and then validated the resulting Figure 2 . Application of the sex, contralateral occlusion, age, and restenosis (SCAR) rule to the pooled data on procedural risk of stroke and death from the 3 large randomized trials of carotid endarterectomy (CEA) versus carotid angioplasty and stenting (CAS) 
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December 2013 rule in the largest available data set of randomized trial data comparing CAS with CEA. In this validation analysis, the results were highly consistent across trials. In the pooled data set of the 3 major European trials, the SCAR-negative patients accounted for about one fourth of the population, although patients with restenosis after previous CEA were excluded from the trials. Thus, in clinical practice, the rule would allow clinicians to identify those patients who might be able to undergo CAS without a higher procedural risk of stroke and death than with CEA (ie, patients with restenosis or contralateral occlusion and women aged <75 years).
In most trials and registries of patients with carotid stenosis, women account for about one third of the population recruited. Randomized trials of CEA for both symptomatic and asymptomatic carotid stenosis and systematic reviews of observational data have demonstrated that benefit is decreased in women, partly because of a high operative risk, which is independent of age. 8, 21, 22 By contrast, whether there are also sex differences in risk of CAS has remained uncertain. 11, 23, 24 By pooling all available data, we have confirmed that women are at higher risk of procedural stroke or death after CEA and shown that there is no evidence of an increased risk of periprocedural stroke or death after CAS, the risk being slightly higher in men. This sex difference between CEA and CAS mainly results from a higher risk of periprocedural complications after CEA in women, which has been attributed to sex differences in carotid size and in the nature of the atheromatous plaque. 25, 26 Less than 10% of patients with severe carotid artery stenosis have contralateral carotid occlusion. Most studies that analyzed the impact of contralateral carotid occlusion on procedural risks after CEA had limited statistical power, with inconsistent findings. 27 Although it has been suggested that routine use of shunts during CEA may reduce the risk of complications in this situation, 28 there is no strong evidence to support this view. 29 On the basis that the duration of carotid occlusion is shorter during CAS than during CEA, some authors have suggested that endovascular therapy might be preferable in patients with contralateral occlusion, but there was little evidence. [30] [31] [32] Our systematic review showing that patients with severe carotid stenosis and contralateral carotid occlusion are at high risk of periprocedural complications after CEA, but not after CAS, and the validation on RCTs provide useful new evidence and have practical implications.
Although previous meta-analyses of RCTs and registries have consistently shown that age has only a small impact on the risk of complications after CEA, 8 elderly patients have been considered at high surgical risk and therefore to be potentially good candidates for CAS by several authors. 13, [33] [34] [35] However, as shown in our previous systematic reviews, [7] [8] [9] [10] [11] and more recently in RCTs, 2, 7 increasing age has more impact on the procedural risk of CAS than CEA. This is also in agreement with studies showing that elderly patients are more likely to have tortuous and severely calcified vessels, resulting in an increased risk of embolization during wire manipulation and catheter exchanges at some stage in CAS. 12, 36, 37 Restenosis occurs in ≥10% of patients treated by CEA, 38 and is generally attributed to neointimal hyperplasia during the early postoperative period or recurrent atherosclerosis thereafter. Although most carotid restenoses are asymptomatic, reoperation has been considered necessary in ≤8% of patients.
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Surgical treatment for recurrent carotid stenosis is more technically difficult than primary procedures, notably because dissection of the neck tissues and the artery is more challenging. Several authors and guidelines have suggested that CAS may be the preferred treatment for post-CEA restenosis. 40, 41 Using all available data, we have shown that in comparison with primary stenosis, restenosis is associated with a higher risk of stroke or death after CEA, but with a lower risk after CAS. We could not validate the finding in RCT data, but an RCT comparing CEA with CAS specifically in patients with carotid restenosis is unlikely to be performed in the future.
Our analysis has several potential limitations. First, because, the European RCTs did not include asymptomatic stenosis, further studies are required to validate the rule in this situation. However, there is no evidence from the literature suggesting a potential interaction between the clinical indication and any of the components of the SCAR rule concerning the periprocedural risk of stroke or death after CEA or CAS, and the components of the rule were identified from studies that included both symptomatic and asymptomatic patients. Second, a recent analysis of data from the CREST trials suggested that women have a higher risk of periprocedural stroke or death after CAS (5.5% versus 3.7%).
24 However, the treatment-by-sex interaction was not significant, and the results are not consistent with other trial data or case series, and no results were reported for women <75 years. 23 Moreover, these CREST data were included in our meta-analyses, with little effects on the overall estimates. Third, the cutoff we used for age may be questionable. Indeed, the pooled analysis of the European trials and CREST have detected an interaction between age and treatment effect, with a crossover at an age of ≈70 years; CAS being better at younger ages, and CEA better at older ages. 2, 7 However, in most observational studies, the cutoffs used to categorize patients were either 75 or 80 years, and SCAR-positive patients <70 years were still at higher risk for procedural stroke or death after CAS compared with CEA in the CSTC data set. Fourth, we were unable to study some potential risk factors attributable to limited availability of published data from observational studies or lack of collection of data in the randomized trials. For instance, technical and anatomic factors, especially extreme angulation of the carotid artery or calcifications, can have an impact on the risks of CAS, 12 but there are few similar data published for CEA. We have also not been able to analyze patients according to both protection device systems and the risk factors simultaneously. However, there is no known interaction between the use of protection device systems and risk factors we examined. Leukoariaosis has been shown to be a risk factor for CEA in NASCET, 42 and also for CAS in ICSS, 43 but has not been widely studied. Similarly, the RR of periprocedural stroke or death in relation to the timing of the procedure might differ between CAS and CEA, 9,44 but definitions of early and late intervention differ widely in observational studies. Fifth, although the pooled absolute risks of periprocedural stroke or death in SCAR-negative patients were identical between CAS and CEA in the validation population, our approach cannot formally demonstrate noninferiority. Finally, although the rule can already be considered useful for clinical practice, further refinement will be required in the future, notably to identify the best option between the 2 potential rules we tested. Contributors: The study was conceived by P.M. Rothwell, and the protocol was drafted by E. Touzé and L. Trinquart. E. Touzé, L. Trinquart, R. Felgueiras, K. Rerkasem, and G. Meliksetyan were responsible for data collection. E. Touzé, L. Trinquart, and P.M. Rothwell were responsible for data analysis, data interpretation, and preparation of the report. L.H. Bonati, J.-L. Mas, P.A. Ringleb, and M.M. Brown provided data from the CSTC. All authors contributed to data interpretation, critical revision of the report, and approved the final version.
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